Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors:
- Sitah AlotaibiSASitah Alotaibi
- Mazen BostajiMBMazen Bostaji
- Anas AlharbiAAAnas Alharbi
- Latifa AlaqeelLALatifa Alaqeel
- Ghaida AlsharifGAGhaida Alsharif
- Afaf AlbalawiAAAfaf Albalawi
- Naif AloufiNANaif Aloufi
- Khaled KhormiKKKhaled Khormi
- Wedad AlmarhbiWAWedad Almarhbi
- Seham AbulkhairSASeham Abulkhair
- Turki AlshaikhTATurki Alshaikh
- Abdullah AlmaqhawiAbdullah Almaqhawi
Open Access
Abstract
Background: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and seasonal influenza is a recognized trigger of acute cardiovascular events. The influenza vaccine has been proposed as a secondary preventative measure, though the benefits regarding mortality and cardiovascular events are unclear. Objective: This study aimed to establish the efficacy of influenza vaccination in lowering mortality and major cardiovascular events in adults suffering from established CVD. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. Eligible studies were identified from PubMed, Google Scholar, and The Cochrane Central Register of Controlled Trials (CENTRAL) through November 2025. RCTs involving adults with established CVD evaluating influenza vaccine impact in comparison to placebo or standard care were included. The Cochrane Risk of Bias tool 2 was used to evaluate study quality. Results: A total of eight RCTs met the inclusion criteria. Influenza vaccination was associated with a statistically significant decrease in the composite outcome (of all-cause mortality, acute myocardial infarction, and stent thrombosis) (OR 0.71, 95% CI 0.57–0.90; p = 0.004; I2 = 0%) and major adverse cardiovascular events (OR 0.44, 95% CI 0.26–0.74; p = 0.002; I2 = 0%). Cardiovascular mortality was found to be significantly lower in the vaccination group (OR 0.64, 95% CI 0.47–0.86; p = 0.003). However, all-cause mortality was not significantly reduced (OR 1.13, 95% CI 0.79–1.62; p = 0.50; I2 = 88%). Conclusions: Influenza vaccination was associated with a reduction in combined cardiovascular events and mortality due to cardiovascular causes in adults diagnosed with established CVD. In contrast, all-cause mortality was not significantly reduced, and the evidence for this outcome was inconclusive. This supports the routine use of the vaccine as an adjunctive measure in the secondary prevention of CVD.Keywords
This publication has 37 references indexed in Scilit:
- ISHLT Statement on Vaccines in Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2025
- Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023JACC, 2025
- Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trialsTravel Medicine and Infectious Disease, 2024
- Risk of cardiovascular events after influenza infection-related hospitalizations in adults with congenital heart disease: A nationwide population based studyAmerican Heart Journal, 2024
- Association of Influenza Vaccination With Cardiovascular RiskJAMA Network Open, 2022
- Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular DiseaseJAMA, 2021
- The Global Burden of Cardiovascular Diseases and RisksJACC, 2020
- Seasonal Influenza Infections and Cardiovascular Disease MortalityJAMA Cardiology, 2016
- Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk PatientsJAMA, 2013
- Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study One-year follow-upEuropean Heart Journal, 2004